Pardanani A - Search Results

1

Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.

Hussein K, Abdel-Wahab O, Lasho TL, Van Dyke DL, Levine RL, Hanson CA, Pardanani A, Tefferi A. Hussein K, et al. Among authors: pardanani a. Am J Hematol. 2010 Jan;85(1):81-3. doi: 10.1002/ajh.21562. Am J Hematol. 2010. PMID: 19957346 Free PMC article.

2

Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.

Baek JY, Tefferi A, Pardanani A, Li CY. Baek JY, et al. Among authors: pardanani a. Leuk Res. 2002 Jan;26(1):83-90. doi: 10.1016/s0145-2126(01)00102-3. Leuk Res. 2002. PMID: 11734306

3

Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease.

Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A. Pardanani A, et al. Leuk Res. 2003 Aug;27(8):739-42. doi: 10.1016/s0145-2126(02)00303-x. Leuk Res. 2003. PMID: 12801532

4

Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.

Pardanani A, Reeder T, Li CY, Tefferi A. Pardanani A, et al. Leuk Res. 2003 Oct;27(10):883-5. doi: 10.1016/s0145-2126(03)00065-1. Leuk Res. 2003. PMID: 12860006

5

Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?

Tefferi A, Pardanani A, Li CY. Tefferi A, et al. Among authors: pardanani a. Blood. 2003 Oct 15;102(8):3073-4; author reply 3074. doi: 10.1182/blood-2003-07-2274. Blood. 2003. PMID: 14527892 Free article. No abstract available.

6

Clinical, genetic, and therapeutic insights into systemic mast cell disease.

Tefferi A, Pardanani A. Tefferi A, et al. Among authors: pardanani a. Curr Opin Hematol. 2004 Jan;11(1):58-64. doi: 10.1097/00062752-200401000-00009. Curr Opin Hematol. 2004. PMID: 14676628 Review.

7

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.

Pardanani A, Tefferi A. Pardanani A, et al. Leuk Res. 2004 May;28 Suppl 1:S47-52. doi: 10.1016/j.leukres.2003.10.006. Leuk Res. 2004. PMID: 15036941 Review.

8

Systemic mastocytosis: current concepts and treatment advances.

Tefferi A, Pardanani A. Tefferi A, et al. Among authors: pardanani a. Curr Hematol Rep. 2004 May;3(3):197-202. Curr Hematol Rep. 2004. PMID: 15087068 Review.

9

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

Pardanani A, Tefferi A. Pardanani A, et al. Blood. 2004 Oct 1;104(7):1931-9. doi: 10.1182/blood-2004-01-0246. Epub 2004 May 27. Blood. 2004. PMID: 15166033 Free article. Review.

10

Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Tefferi A, Pardanani A. Tefferi A, et al. Among authors: pardanani a. Int J Hematol. 2004 Jun;79(5):441-7. doi: 10.1532/ijh97.04046. Int J Hematol. 2004. PMID: 15239393 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

463 results

Search Page

Filters